Predictive Health Intelligence unveils CLDI

Predictive Health Intelligence announced a promising new method, the Cumulative Liver Damage Index (CLDI), for earlier identification of serious liver disease using existing United Kingdom — National Health Service blood test data. The findings from the LiveWell study, presented at a major European liver congress, indicate that CLDI is more effective than standard tests at identifying clinically significant liver disease by analyzing long-term liver damage patterns. This approach, delivered via hepatoSIGHT technology, could streamline patient care by allowing high-risk individuals to be referred directly for liver scans, reducing unnecessary appointments. The study, which recruited 994 participants from Bolton NHS Foundation Trust, was supported by Sano Genetics for genetic profiling and Tawazun Health for liver scans. Co-founders Tim Jobson and Neil Stevens, along with Larry R. Holden of the Global Liver Institute, highlighted the potential for improved patient outcomes and reduced healthcare burden. A larger follow-up study involving 8,000 patients is underway, with further United Kingdom — National Health Service rollout of hepatoSIGHT planned for 2027. The work received funding from United Kingdom — Innovate UK and the United Kingdom — National Institute for Health and Care Research.